According To Mr He Combined A Cobalt Amine Clinical Observation On Treatment Of Diabetic Peripheral Neuropathy And Its Relationship With Oxidative Stress Research

Objective: To compare the efficacy of epalrestat, mecobalamine, and combinationthearpy of them in type2diabetic patients with diabetic peripheral neuropathy (DPN),and the association with oxidative stress and chronic inflammation.Methods: A total of60type2diabetic patients with diabetic peripheral neuropathywere enrolled. They were randomly allocated to three groups: epalrestat50mg threetimes daily (E group); methylcobalamin0.5mg three times daily (M group);combination therapy of epalrestat50mg and methylcobalamin0.5mg three timesdaily (EM group) for12weeks. Electrophysiological examinations were conductedbefore randomization and at the end of study, Oxidative stress was estimated byplasma8-iso prostaglandin F2α (8-iso-PGF2α), and Interleukin-6(IL-6) as aparameter of inflammation. We used the patients’ questionnaires of Michiganneuropathy screening instrument (MNSI) and Michigan diabetic neuropathy score(MDNS) to evaluate subjective symptoms and signs. The primary outcomes includedchanges in Motor nerve conduction velocity (MCV), sensory nerve conductionvelocity (SCV), and minimum F-wave latency, the score of MNSI questionaires andMDNS, plasma8-iso-PGF2α and IL-6. Data was analyzed using paired t test, Chisquare test, analysis of variance (ANOVA).Results: The EM group showed significant suppression of deterioration of SCV in inthe sural nerve and significant relief in subjective symptoms compared to the othertwo group after12weeks (P <0.05). There was a significant difference in change in8-iso-PGF2α level in EM group compared to the other two group.Conclusions: Epalrestat and methylcobalamin combination therapy only suppressedthe deterioration of diabetic peripheral neuropathy in the lower extremity. And could relieve subjective symptoms significantly. Its effects might be associated with thesuppression of oxidative stress. Objective: To investigate the levels and clinical significance of serum IL-6、8-iso-PGF2α in diabetic peripheral neuropathy patients.Methods:25T2DM（Type2Diabetic Mellitus） patients，55DPN（DiabeticPeripheral Neuropathy） patients，and25health people were chosen. Serum IL-6、in the3groups were detected through ELASA.Results: Serum IL-6and8-iso-PGF2α level were significantly higher in the DM andDPN groups than the control group（P <0.05)； Serum IL-6level was higher in theDPN group than in the DM group，but there was no significantly difference betweentwo groups（P>0.05)；Serum8-iso-PGF2α level was significantly higher in the DPNgroup than in DM group (P <0.05).Conclusion: This research showed the8-iso-PGF2α had effect in the diabetes anddiabetes nerve pathological changes, it can be considered as biomarker od DPN. Butit was not considered that IL-6had effect on DPN.